FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2588394773> ?p ?o ?g. }

• W2588394773 abstract "Abstract Abstract 2074 Induction of fetal hemoglobin (HbF) has proven therapeutic potential to treat sickle cell disease and β-thalassemia. However, agents known to be effective in humans, including hydroxyurea, DNMT inhibitors and butyrate derivatives are not ideal due to suppression of hematopoiesis and the possibility of long-term side effects. Two natural compounds, angelicin (Lampronti, et al, Eur J Hematol 2003) and resveratrol (Rodrigue, et al, Hematology 2001) have been found to induce γ-globin gene expression in K562 cells. These agents may be important lead compounds as they are generally non-cytotoxic and are being evaluated in ongoing human trials as cancer chemopreventative agents where these and several other agents are thought to work by activating antioxidant response pathway genes. The products of these genes are enzymes involved in antioxidant and detoxification activities and include NADPH-quinone oxireductase 1 (NQO1), glutamate-cysteine ligase (GCL) and glutathione S-transferase (GST). The activation of these genes is mediated by the transcription factor, NF-E2 related factor 2 (NRF2), which binds to a specific antioxidant response element (ARE) sequence (TGACnnnGCA) in target gene promoters. The proximal γ-globin promoter contains an ARE sequence between the two CAAT boxes, suggesting that it too may be activated by NRF2. This led us to hypothesize that drugs that activate the ARE/NRF2 pathway may provide a less toxic approach to HbF induction. To test this hypothesis, we treated K562 cells with various NRF2 pathway activators. We initially tested six compounds that are known to induce antioxidant response genes at doses that did not inhibit proliferation and found the most pronounced γ-globin induction with tert-butylhydroquinone (tBHQ) (2.8 fold). We next tested tBHQ in two different primary cell culture models: erythroid precursors isolated from normal human bone marrow and in vitro erythroid differentiation of primary human CD34+ cells. In both of these models, tBHQ treatment increased γ-globin steady state mRNA levels and induced expression of NRF2 target genes. Treatment of differentiating erythroid cells caused a dose dependent increase in γ/(γ+β) mRNA and % HbF. HPLC analysis revealed the highest non-toxic concentration of tBHQ, 5μM, produced 10% HbF while the positive control, 0.5μM of 5-Azacytidine, resulted in 12% HbF compared to the untreated control at 3%. Since similar mRNA induction was seen in K562 cells, we used these cells to characterize the mechanism of tBHQ induced γ-globin expression. First, we used siRNA to decrease NRF2 mRNA levels. This resulted in a greater than 75% knockdown of NRF2 mRNA and protein and reduced tBHQ induction of γ-globin and NQO1 gene expression by 90% and 75%, respectively, compared to samples transfected with scrambled siRNA (p < 0.01). Subsequent experiments showed that tBHQ treatment resulted in NRF2 translocation to the nucleus and binding to the NQO1 and γ-globin promoters but not at negative control sites. In addition, inducing NRF2 translocation by transiently suppressing levels of its inhibitor, KEAP1, did not result in full induction of γ-globin mRNA expression, suggesting that NRF2 translocation alone is not sufficient for γ-globin induction. However, when combined with tBHQ, suppression of KEAP1 did enhance γ-globin induction. Taken together, these results suggest that NRF2/ARE pathway activation induces γ-globin mRNA expression and HbF production in primary human erythroid cells and that this is a promising strategy for further pre-clinical development. Disclosures: No relevant conflicts of interest to declare." @default.
• W2588394773 created "2017-02-24" @default.
• W2588394773 creator A5016323341 @default.
• W2588394773 creator A5024508035 @default.
• W2588394773 creator A5028953613 @default.
• W2588394773 date "2010-11-19" @default.
• W2588394773 modified "2023-10-01" @default.
• W2588394773 title "Exploiting the NRF2/Antioxidant Response Element Signaling Pathway to Induce γ-Globin Gene Expression and HbF Production" @default.
• W2588394773 doi "https://doi.org/10.1182/blood.v116.21.2074.2074" @default.
• W2588394773 hasPublicationYear "2010" @default.
• W2588394773 type Work @default.
• W2588394773 sameAs 2588394773 @default.
• W2588394773 citedByCount "0" @default.
• W2588394773 crossrefType "journal-article" @default.
• W2588394773 hasAuthorship W2588394773A5016323341 @default.
• W2588394773 hasAuthorship W2588394773A5024508035 @default.
• W2588394773 hasAuthorship W2588394773A5028953613 @default.
• W2588394773 hasConcept C104317684 @default.
• W2588394773 hasConcept C153911025 @default.
• W2588394773 hasConcept C171122931 @default.
• W2588394773 hasConcept C172680121 @default.
• W2588394773 hasConcept C181199279 @default.
• W2588394773 hasConcept C2776317666 @default.
• W2588394773 hasConcept C2779234561 @default.
• W2588394773 hasConcept C2779881523 @default.
• W2588394773 hasConcept C2781173740 @default.
• W2588394773 hasConcept C538909803 @default.
• W2588394773 hasConcept C54355233 @default.
• W2588394773 hasConcept C55493867 @default.
• W2588394773 hasConcept C86803240 @default.
• W2588394773 hasConceptScore W2588394773C104317684 @default.
• W2588394773 hasConceptScore W2588394773C153911025 @default.
• W2588394773 hasConceptScore W2588394773C171122931 @default.
• W2588394773 hasConceptScore W2588394773C172680121 @default.
• W2588394773 hasConceptScore W2588394773C181199279 @default.
• W2588394773 hasConceptScore W2588394773C2776317666 @default.
• W2588394773 hasConceptScore W2588394773C2779234561 @default.
• W2588394773 hasConceptScore W2588394773C2779881523 @default.
• W2588394773 hasConceptScore W2588394773C2781173740 @default.
• W2588394773 hasConceptScore W2588394773C538909803 @default.
• W2588394773 hasConceptScore W2588394773C54355233 @default.
• W2588394773 hasConceptScore W2588394773C55493867 @default.
• W2588394773 hasConceptScore W2588394773C86803240 @default.
• W2588394773 hasLocation W25883947731 @default.
• W2588394773 hasOpenAccess W2588394773 @default.
• W2588394773 hasPrimaryLocation W25883947731 @default.
• W2588394773 hasRelatedWork W1739046261 @default.
• W2588394773 hasRelatedWork W1854934447 @default.
• W2588394773 hasRelatedWork W1972039645 @default.
• W2588394773 hasRelatedWork W1990425278 @default.
• W2588394773 hasRelatedWork W2028673321 @default.
• W2588394773 hasRelatedWork W2032631038 @default.
• W2588394773 hasRelatedWork W2073707788 @default.
• W2588394773 hasRelatedWork W2084429681 @default.
• W2588394773 hasRelatedWork W2092039013 @default.
• W2588394773 hasRelatedWork W2099913359 @default.
• W2588394773 hasRelatedWork W2107224084 @default.
• W2588394773 hasRelatedWork W2118823194 @default.
• W2588394773 hasRelatedWork W2135548066 @default.
• W2588394773 hasRelatedWork W2146962699 @default.
• W2588394773 hasRelatedWork W2153249134 @default.
• W2588394773 hasRelatedWork W2286917400 @default.
• W2588394773 hasRelatedWork W2321001445 @default.
• W2588394773 hasRelatedWork W2593297270 @default.
• W2588394773 hasRelatedWork W3198795714 @default.
• W2588394773 hasRelatedWork W2766826134 @default.
• W2588394773 isParatext "false" @default.
• W2588394773 isRetracted "false" @default.
• W2588394773 magId "2588394773" @default.
• W2588394773 workType "article" @default.